Cellebrite DI (NASDAQ:CLBT) Trading Down 7.3% - Should You Sell?

Key Points

• Shares fell about 7.3% to roughly $12.45 on Thursday (low $12.44) on ~762,471 shares traded, a 57% decline from average daily volume, after closing at $13.43 the prior session.
• Analyst moves were mixed: Needham cut its target from $24 to $18 but kept a "buy," and the stock's consensus is a "Moderate Buy" with an average target of $22.50 (four buys, one sell).
• Cellebrite reported quarterly $0.14 EPS (in line) and revenue of $128.8M (above estimates) with revenue up 28.8% year‑over‑year, while the company carries a ~$3.03B market cap and a trailing P/E of 39.00.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) shares dropped 7.3% during trading on Thursday . The stock traded as low as $12.44 and last traded at $12.4450. Approximately 762,471 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 1,764,511 shares. The stock had previously closed at $13.43.

Analysts Set New Price Targets

CLBT has been the subject of several research analyst reports. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Cellebrite DI in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Cellebrite DI Trading Down 9.4%

The company has a market cap of $3.03 billion, a PE ratio of 39.00, a P/E/G ratio of 2.15 and a beta of 1.28. The firm has a 50 day moving average of $14.13 and a two-hundred day moving average of $16.55.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The company had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm's quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Institutional Trading of Cellebrite DI

A number of institutional investors and hedge funds have recently bought and sold shares of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Cellebrite DI by 16.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock valued at $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Geode Capital Management LLC increased its stake in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock valued at $5,029,000 after purchasing an additional 43,898 shares in the last quarter. Invesco Ltd. increased its stake in Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock valued at $56,089,000 after purchasing an additional 209,473 shares in the last quarter. First Trust Advisors LP bought a new stake in Cellebrite DI during the 2nd quarter valued at about $341,000. Finally, Marshall Wace LLP bought a new stake in Cellebrite DI during the 2nd quarter valued at about $4,472,000. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.